Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2008

Open Access 01-12-2008 | Research

An integrative model for recurrence in ovarian cancer

Authors: Alexandros Laios, Sharon A O'Toole, Richard Flavin, Cara Martin, Martina Ring, Noreen Gleeson, Tom D'Arcy, Eamonn PJ McGuinness, Orla Sheils, Brian L Sheppard, John J O' Leary

Published in: Molecular Cancer | Issue 1/2008

Login to get access

Excerpt

Ovarian cancer is one of the commonest cancers in women and the leading cause of death from gynaecological malignancy in the western world. About 205,000 cases of ovarian cancer are diagnosed worldwide each year [1]. It accounts for 3% of female cancers in Ireland with over 350 new cases each year [2]. Marked heterogeneity is a hallmark of the disease, not only in tumor histotype and grade but also in response to chemotherapy and overall prognosis [3]. Over 90% of cases arise from the surface epithelium. Serous adenocarcinomas are the commonest and account for 40%–50% of malignant neoplasms [4]. …
Appendix
Available only for authorised users
Literature
1.
Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 2005, 55: 74-108.CrossRefPubMed
2.
3.
Wang V, Li C, Lin M, Welch W, Bell D, Wong YF, Berkowitz R, Mok SC, Bandera CA: Ovarian cancer is a heterogeneous disease. Cancer Genet Cytogenet. 2005, 161: 170-173.CrossRefPubMed
4.
DiSaia PJ, Creasman WT, : Epithelial ovarian cancer. Clinical gynecologic oncology. 1997, 282-350. St. Louis: Mosby Year Book
5.
Kikkawa F, Nawa A, Ino K, Shibata K, Kajiyama H, Nomura S: Advances in treatment of epithelial ovarian cancer. Nagoya J Med Sci. 2006, 68: 19-26.PubMed
6.
Zhang X, Feng J, Cheng Y, Yao Y, Ye X, Fu T, Cheng H: Characterization of differentially expressed genes in ovarian cancer by cDNA microarrays. Int J Gynecol Cancer. 2005, 15: 50-57.CrossRefPubMed
7.
Schaner ME, Ross DT, Ciaravino G, Sorlie T, Troyanskaya O, Diehn M, Wang YC, Duran GE, Sikic TL, Caldeira S: Gene expression patterns in ovarian carcinomas. Mol Biol Cell. 2003, 14: 4376-4386.PubMedCentralCrossRefPubMed
8.
Tapper J, Kettunen E, El-Rifai W, Seppala M, Andersson LC, Knuutila S: Changes in gene expression during progression of ovarian carcinoma. Cancer Genet Cytogenet. 2001, 128: 1-6.CrossRefPubMed
9.
Selvanayagam ZE, Cheung TH, Wei N, Vittal R, Kit Lo KW, Yeo W, Kita T, Ravatn R, Hung Chung TK, Wong YF, Chin K-V: Prediction of chemotherapeutic response in ovarian cancer with DNA microarray expression profiling. Cancer Genetics and Cytogenetics. 2004, 154: 63-66. 10.1016/j.cancergencyto.2004.01.024.CrossRefPubMed
10.
De Smet F, Pochet NL, Engelen K, Van Gorp T, Van Hummelen P, Marchal K, Amant F, Timmerman D, De Moor BL, Vergote IB: Predicting the clinical behavior of ovarian cancer from gene expression profiles. Int J Gynecol Cancer. 2006, 16 (Suppl 1): 147-151.CrossRefPubMed
11.
O'Toole SA, Sheppard BL, McGuinness E, Gleeson NC, Bonnar J: Serous papillary adenocarcinomas of the ovary display heterogeneity in their response to chemotherapy. International Journal of Gynecological Cancer. 2001, 11: 365-371.CrossRefPubMed
12.
O'Toole SA, Sheppard BL, Laios A, O'Leary JJ, McGuinness EPJ, D'Arcy T, Bonnar J: Potential predictors of chemotherapy response in ovarian cancer – How do we define chemosensitivity?. Gynecologic Oncology. 2007, 104: 345-351.CrossRefPubMed
13.
14.
Skipper HE: Kinetics of mammary tumor cell growth and implications for therapy. Cancer. 1971, 28: 1479-1499.CrossRefPubMed
15.
Di Nicolantonio F, Mercer S, Knight L, Gabriel F, Whitehouse P, Sharma S, Fernando A, Glaysher S, Di Palma S, Johnson P: Cancer cell adaptation to chemotherapy. BMC Cancer. 2005, 5: 78-PubMedCentralCrossRefPubMed
16.
17.
Lin J, Yang Q, Yan Z, Markowitz J, Wilder PT, Carrier F, Weber DJ: Inhibiting S100B Restores p53 Levels in Primary Malignant Melanoma Cancer Cells. J Biol Chem. 2004, 279: 34071-34077.CrossRefPubMed
18.
Baudier J, Delphin C, Grunwald D, Khochbin S, Lawrence JJ: Characterization of the Tumor Suppressor Protein p53 as a Protein Kinase C Substrate and a S100b-Binding Protein. PNAS. 1992, 89: 11627-11631.PubMedCentralCrossRefPubMed
19.
Stewart JJ, White JT, Yan X, Collins S, Drescher CW, Urban ND, Hood L, Lin B: Proteins associated with Cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels. Mol Cell Proteomics. 2006, 5: 433-443.CrossRefPubMed
20.
Sorci G, Agneletti AL, Donato R: Effects of S100A1 and S100B on microtubule stability. An in vitro study using triton-cytoskeletons from astrocyte and myoblast cell lines. Neuroscience. 2000, 99: 773-783.CrossRefPubMed
21.
Shen D-W, Liang X-J, Gawinowicz MA, Gottesman MM: Identification of Cytoskeletal [14C]Carboplatin-Binding Proteins Reveals Reduced Expression and Disorganization of Actin and Filamin in Cisplatin-Resistant Cell Lines. Mol Pharmacol. 2004, 66: 789-793.CrossRefPubMed
22.
Sherman-Baust CA, Weeraratna AT, Rangel LBA, Pizer ES, Cho KR, Schwartz DR, Shock T, Morin PJ: Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell. 2003, 3: 377-386.CrossRefPubMed
23.
Sonoda N, Furuse M, Sasaki H, Yonemura S, Katahira J, Horiguchi Y, Tsukita S: Clostridium perfringens enterotoxin fragment removes specific claudins from tight junction strands: Evidence for direct involvement of claudins in tight junction barrier. J Cell Biol. 1999, 147: 195-204.PubMedCentralCrossRefPubMed
24.
Cheung ST, Leung KL, Ip YC, Chen X, Fong DY, Ng IO, Fan ST, So S: Claudin-10 expression level is associated with recurrence of primary hepatocellular carcinoma. Clin Cancer Res. 2005, 11: 551-556.PubMed
25.
Gonzalez-Mariscal L, Betanzos A, Avila-Flores A: MAGUK proteins: structure and role in the tight junction. Seminars in Cell & Developmental Biology. 2000, 11: 315-324.CrossRef
26.
Frisch SM, Francis H: Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol. 1994, 124: 619-626.CrossRefPubMed
27.
Morin PJ: Drug resistance and the microenvironment: nature and nurture. Drug Resistance Updates. 2003, 6: 169-172.CrossRefPubMed
28.
Wilson J, Balkwill F: The role of cytokines in the epithelial cancer microenvironment. Seminars in Cancer Biology. 2002, 12: 113-120.CrossRefPubMed
29.
Wang Y, Yang J, Gao Y, Du Y, Bao L, Niu W, Yao Z: Regulatory effect of e2, IL-6 and IL-8 on the growth of epithelial ovarian cancer cells. Cell Mol Immunol. 2005, 2: 365-372.PubMed
30.
Apte SM, Vadhan-Raj S, Cohen L, Bassett RL, Gordon IO, Levenback CF, Ramirez PT, Gallardo ST, Patenia RS, Garcia ME: Cytokines, GM-CSF and IFNgamma administered by priming and post-chemotherapy cycling in recurrent ovarian cancer patients receiving carboplatin. J Transl Med. 2006, 4: 16-PubMedCentralCrossRefPubMed
31.
Voronov E, Shouval DS, Krelin Y, Cagnano E, Benharroch D, Iwakura Y, Dinarello CA, Apte RN: IL-1 is required for tumor invasiveness and angiogenesis. PNAS. 2003, 100: 2645-2650.PubMedCentralCrossRefPubMed
32.
Shao J, Sheng H: Prostaglandin E2 Induces the Expression of IL-1{alpha} in Colon Cancer Cells. J Immunol. 2007, 178: 4097-4103.CrossRefPubMed
33.
Tanner MM, Grenman S, Koul A, Johannsson O, Meltzer P, Pejovic T, Borg A, Isola JJ: Frequent Amplification of Chromosomal Region 20q12–q13 in Ovarian Cancer. Clin Cancer Res. 2000, 6: 1833-1839.PubMed
34.
Quinlan KGR, Verger A, Yaswen P, Crossley M: Amplification of zinc finger gene 217 (ZNF217) and cancer: When good fingers go bad. Biochimica et Biophysica Acta (BBA) – Reviews on Cancer. 2007, 1775: 333-340. 10.1016/j.bbcan.2007.05.001.CrossRef
35.
Collins C, Rommens JM, Kowbel D, Godfrey T, Tanner M, Hwang S-i, Polikoff D, Nonet G, Cochran J, Myambo K: Positional cloning of ZNF217 and NABC1: Genes amplified at 20q13.2 and overexpressed in breast carcinoma. Proceedings of the National Academy of Sciences. 1998, 95: 8703-8708. 10.1073/pnas.95.15.8703.CrossRef
36.
Schlessinger J: Common and Distinct Elements in Cellular Signaling via EGF and FGF Receptors. Science. 2004, 306: 1506-1507.CrossRefPubMed
37.
Normanno N, Bianco C, De Luca A, Maiello MR, Salomon DS: Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer. 2003, 10: 1-21.CrossRefPubMed
38.
Scambia G, Benedetti Panici P, Battaglia F, Ferrandina G, Baiocchi G, Greggi S, De Vincenzo R, Mancuso S: Significance of epidermal growth factor receptor in advanced ovarian cancer. J Clin Oncol. 1992, 10: 529-535.PubMed
39.
Posters: 6. Epidemiology/Pathology. Ann Oncol. 2002, 13: 65-68.
40.
Fischer OM, Hart S, Gschwind A, Ullrich A: EGFR signal transactivation in cancer cells. Biochem Soc Trans. 2003, 31: 1203-1208.CrossRefPubMed
41.
P Oc, Wongkajornsilp A, Rhys-Evans PH, Eccles SA: Signaling pathways required for matrix metalloproteinase-9 induction by betacellulin in head-and-neck squamous carcinoma cells. Int J Cancer. 2004, 111: 174-183.CrossRef
42.
Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C, Ullrich A: EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature. 1999, 402: 884-888.PubMed
43.
Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW: Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene. 2004, 23: 2934-2949.CrossRefPubMed
44.
Cowden Dahl KD, Zeineldin R, Hudson LG: PEA3 Is Necessary for Optimal Epidermal Growth Factor Receptor-Stimulated Matrix Metalloproteinase Expression and Invasion of Ovarian Tumor Cells. Mol Cancer Res. 2007, 5: 413-421.PubMedCentralCrossRefPubMed
45.
Rintoul RC, Sethi T: The role of extracellular matrix in small-cell lung cancer. The Lancet Oncology. 2001, 2: 437-442.CrossRefPubMed
46.
Gupta GP, Nguyen DX, Chiang AC, Bos PD, Kim JY, Nadal C, Gomis RR, Manova-Todorova K, Massague J: Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature. 2007, 446: 765-770.CrossRefPubMed
47.
Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C: Patterns of somatic mutation in human cancer genomes. Nature. 2007, 446: 153-158.PubMedCentralCrossRefPubMed
48.
Chaffer CL, Dopheide B, Savagner P, Thompson EW, Williams ED: Aberrant fibroblast growth factor receptor signaling in bladder and other cancers. Differentiation. 2007, 75: 831-842.CrossRefPubMed
49.
Miyake H, Yoshimura K, Hara I, Eto H, Arakawa S, Kamidono S: Basic Fibroblast Growth Factor Regulates Matrix Metalloproteinases Production and In Vitro Invasiveness in Human Bladder Cancer Cell Lines. The Journal of Urology. 1997, 157: 2351-2355.CrossRefPubMed
50.
Chaffer CL, Brennan JP, Slavin JL, Blick T, Thompson EW, Williams ED: Mesenchymal-to-Epithelial Transition Facilitates Bladder Cancer Metastasis: Role of Fibroblast Growth Factor Receptor-2. Cancer Res. 2006, 66: 11271-11278.CrossRefPubMed
51.
Potti A, Dressman HK, Bild A, Riedel RF, Chan G, Sayer R, Cragun J, Cottrill H, Kelley MJ, Petersen R: Genomic signatures to guide the use of chemotherapeutics. Nat Med. 2006, 12: 1294-1300.CrossRefPubMed
52.
Metadata
Title
An integrative model for recurrence in ovarian cancer
Authors
Alexandros Laios
Sharon A O'Toole
Richard Flavin
Cara Martin
Martina Ring
Noreen Gleeson
Tom D'Arcy
Eamonn PJ McGuinness
Orla Sheils
Brian L Sheppard
John J O' Leary
Publication date
01-12-2008
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2008
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-7-8

Other articles of this Issue 1/2008

Molecular Cancer 1/2008 Go to the issue

Research

Membrane androgen receptor activation triggers down-regulation of PI-3K/Akt/NF-kappaB activity and induces apoptotic responses via Bad, FasL and caspase-3 in DU145 prostate cancer cells

Research

Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile

Research

Sub-megabase resolution tiling (SMRT) array-based comparative genomic hybridization profiling reveals novel gains and losses of chromosomal regions in Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma cell lines

Research

Evidence for efficient phosphorylation of EGFR and rapid endocytosis of phosphorylated EGFR via the early/late endocytic pathway in a gefitinib-sensitive non-small cell lung cancer cell line

Research

Differential expression of metallothioneins (MTs) 1, 2, and 3 in response to zinc treatment in human prostate normal and malignant cells and tissues

Research

Identification of a panel of sensitive and specific DNA methylation markers for squamous cell lung cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits